Floatz logo

Extra Virgin Olive Oil

Cerebral Amyloid Angiopathy

Explore 1 assets in Cerebral Amyloid Angiopathy
Floatz Rating
D30/100
Confidence
Indicative
v0.2Rating updated July 14, 2026
Sponsor
Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta
Modality
UNKNOWN
Development Phase
Unknown
Status
Active
Evidence ledger · v0.2

Clinical Evidence

Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
15Moderate confidence
Detailed axis rationale is planned and will be published soon.

No trial-level evidence is linked to this axis yet.

Competitive Position

Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95Moderate confidence
Detailed axis rationale is planned and will be published soon.

Same indication · Cerebral Amyloid Angiopathy

AssetSponsorPhaseRating
Extra Virgin Olive Oil (this asset)Fondazione I.R.C.C.S. Istituto Neurologico Carlo BestaUnkD · 30

Other indications for Extra Virgin Olive Oil

IndicationSponsorPhaseRating
Cognitive DisorderP2CC · 47
Fatty Liver DiseaseN/AD · 30
Abdominal Obesity-Metabolic SyndromeN/AD · 30

Scientific Foundation

Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR

Planned for methodology v0.2.

Development Feasibility

How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR

Planned for methodology v0.2.

Commercial Opportunity

Commercial prize: addressable population, unmet need, and the value case for the indication.
NR

Planned for methodology v0.2.

IP & Exclusivity

Exclusivity position, covering patent protection and freedom-to-operate runway.
NR

Planned for methodology v0.2.

Manufacturing & Supply

Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR

Planned for methodology v0.2.

Citation

Floatz Terminal. Extra Virgin Olive Oil in Cerebral Amyloid Angiopathy. Methodology v0.2.
Rated under v0.2 effective July 8, 2026. Last refreshed July 14, 2026.
Accessed July 14, 2026.
https://terminal.floatz.ai/assets/extra-virgin-olive-oil-cerebral-amyloid-angiopathy

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →